Intellia Therapeutics, Inc. (NTLA) has a consensus analyst rating of Buy, based on 39 analysts covering the stock. Of those, 28 recommend buying, 10 recommend holding, and 1 recommend selling.
The analyst consensus price target for NTLA is $19.38, representing a +31.1% upside from the current price of $14.78. Price targets range from a low of $7.00 to a high of $48.00.
